Glucocorticoid-Induced Osteoporosis: New Insights into the Pathophysiology and Treatments

被引：126
|
作者：
Lane, Nancy E. [1 ]
机构：
[1] Univ Calif Davis Hlth Syst, Ctr Musculoskeletal Hlth, 4625 Second Ave,Suite 2006, Sacramento, CA 95817 USA
来源：
CURRENT OSTEOPOROSIS REPORTS | 2019年 / 17卷 / 01期
关键词：
Glucocorticoids; Bone cells; Bone vascularity; Osteonecrosis; Parathyroid hormone; PARATHYROID-HORMONE; VERTEBRAL FRACTURE; BONE-DENSITY; RISEDRONATE; PREVENTION; MICE; ALENDRONATE; STRENGTH;
D O I：
10.1007/s11914-019-00498-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of this ReviewThe goal of the review is to provide an updated understanding of the pathophysiology of glucocorticoid-induced osteoporosis and treatment recommendations.Recent FindingsGlucocorticoids reduce osteoblast and osteocyte lifespan and activity and reduce the vascularity of the bone that together may explain the greater reductions in bone strength than those of bone mass. Treatments with parathyroid hormone fragments appear to reverse glucocorticoid-induced bone loss and fracture risk partially through maintaining bone vascularity and bone strength.SummaryThis review identifies how glucocorticoid anti-osteogenic and vascular effects together may reduce bone strength. It also provides guidance to clinicians on rationale treatment for glucocorticoid-induced osteoporosis.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 50 条
  • [21] Management of glucocorticoid-induced osteoporosis
    Messina, Osvaldo D.
    Vidal, Luis Fernando
    Vidal, Maritza Vidal
    Bultink, Irene E. M.
    Raterman, Hennie G.
    Lems, William
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 33 (04) : 793 - 804
  • [22] Glucocorticoid-induced osteoporosis: an update
    Juliet Compston
    Endocrine, 2018, 61 : 7 - 16
  • [23] Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica
    Naranjo, Antonio
    Lopez, Ruben
    Garcia-Magallon, Blanca
    Caceres, Laura
    Francisco, Felix
    Jimenez-Palop, Mercedes
    Ojeda-Bruno, Soledad
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (10) : 1459 - 1463
  • [24] Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis
    Iacopo, Chiodini
    Alberto, Falchetti
    Daniela, Merlotti
    Cristina, Eller Vainicher
    Luigi, Gennari
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (04) : 283 - 298
  • [25] Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
    Serefoglu, Ege Can
    Tandogdu, Zafer
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 219 - 223
  • [26] Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Jiang, Lianghai
    Dong, Jian
    Wei, Jianwei
    Liu, Lantao
    BMC MUSCULOSKELETAL DISORDERS, 2022, 23 (01)
  • [27] The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
    Hasegawa, Eriko
    Ito, Satoshi
    Takai, Chinatsu
    Kobayashi, Daisuke
    Nomura, Yumi
    Otani, Hiroshi
    Abe, Asami
    Ishikawa, Hajime
    Murasawa, Akira
    Narita, Ichiei
    Nakazono, Kiyoshi
    INTERNAL MEDICINE, 2018, 57 (15) : 2169 - 2178
  • [28] Updated recommendations on the management of glucocorticoid-induced osteoporosis
    Orcel, Philippe
    JOINT BONE SPINE, 2014, 81 (06) : 465 - 468
  • [29] Glucocorticoid-induced osteoporosis: treatment update and review
    Fraser, Lisa-Ann
    Adachi, Jonathan D.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2009, 1 (02) : 71 - 85
  • [30] Prophylaxis and therapy of the glucocorticoid-induced osteoporosis - a review of recent guidelines
    Rintelen, Bernhard
    Bobacz, Klaus
    Hoefle, Guenter
    Peichl, Peter
    Rainer, Franz
    Weber, Kurt
    Gaugg, Markus
    WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (21-22) : 633 - 644
12345